| This week's sponsor is Premier Research. | |  | Tackling gene therapy's biggest challenges
Gene therapy holds great promise, but despite revolutionary advances, a clear path from bench to bedside remains elusive. Download the white paper for more tips on seizing this unprecedented opportunity. Premier Research. Built for biotech.
Visit us at BIO International, Booth 4049 to learn more. |
Today's Rundown Featured Story | | | Tuesday, June 4, 2019 The $74 billion deal that will see Bristol-Myers Squibb subsume Celgene into its ranks is all but done, but it’s been a rocky path. Today, Celgene delivered some positive optics for its would-be parent. |
|
|
 | Thank you to Lonza for sponsoring this week's coverage of BIO. |
Top Stories Tuesday, June 4, 2019 José Baselga, AstraZeneca's R&D chief, sat down with FierceBiotech to talk capivasertib data, how to pick the best drug for each patient and what needs to change before cancer is cured. Tuesday, June 4, 2019 Neil Woodford has suspended trading in his flagship fund after investors withdrew £10 million a day last month. The surge in outflows follows sustained poor performance by the fund that culminated in it being among the worst performers in May. Monday, June 3, 2019 Pharma and biopharma have endless data at their disposal. Why aren't they using it? Here's how to make the most of your data for clinical success. Tuesday, June 4, 2019 Just over a month after walking out on troubled cancer biotech Immunomedics, Robert Iannone, M.D., has taken up the research chief job at Jazz Pharmaceuticals. Tuesday, June 4, 2019 Bayer is paying Arvinas $17.5 million upfront to develop protein-degrading treatments for cardiovascular, oncological and gynecological diseases. The partners will apply Arvinas’ targeted protein degrader technology to targets selected by Bayer. Tuesday, June 4, 2019 Inhibrx has filed for a $75 million IPO. The Celgene-partnered single-domain antibody specialist will use the money to complete phase 1 trials of three drugs targeting cancers and rare diseases. Monday, June 3, 2019 In an early trial, 58% of patients with lymphoma that's associated with Epstein-Barr virus (EBV) responded to a combination of Viracta Therapeutics’ HDAC inhibitor nanatinostat and an antiviral drug. The company is now planning a phase 2 study of the combo. Tuesday, June 4, 2019 Trial "matchmaker" Massive Bio, IBM Watson and a host of other organizations have partnered with former Vice President Joe Biden’s Cancer Initiative to help improve patients’ access to and the work coming from cancer studies. Tuesday, June 4, 2019 AstraZeneca's Leif Johansson has put in seven years as chairman, through some big ups and downs—including Pfizer's hostile takeover attempt. Now, the company's starting to scout for a potential successor, Sky News reports. | This week's sponsor is LabConnect. | |  |
LabConnect offers innovative project & data management services connecting samples to data. We customize services to meet the unique needs of clients and their clinical studies. LabConnect is your connection to confidence. Contact us to learn more. |
Resources Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. |
|
